Navigation Links
Benda Pharmaceutical Reports Third Quarter 2008 Financial Results
Date:11/18/2008

rd quarter of 2007, reflecting the penalty payment of $0.3 million referenced above as well as advertising expenditure at SiBiono and Benda Ebei.

Net loss in the third quarter of 2008 was $0.8 million, or a net loss of $0.01 per basic and diluted share, compared to net income of $1.0 million, or net income of $0.01 per basic and diluted share, in the third quarter of 2007.

Charles Wan, Chairman and Chief Executive Officer of Benda, commented, ''We continue to be focused on enhancing our revenue performance at SiBiono, as well as our gross margin performance across the organization. The reorganization of personnel at SiBiono was completed in the third quarter and full-scale production is expected to resume in the fourth quarter of 2008. We continue to be optimistic about the market opportunities for SiBiono in the future.''

    Business Update
    -- Management update: The Company appointed George Zhou as Chief Operating
       Officer, effective August 13, 2008.
    -- Jiangling Benda plant update:  On April 9, 2008, Jiangling Benda
       received the GMP Certificate from the Chinese State Food and Drug
       Administration ("SFDA"), authorizing the production of Ribavirin.  The
       Company believes the certification is a major step toward
       commercializing Ribavirin in the domestic market.  To achieve
       full-scale production and further expansion, management is working with
       local banks to negotiate financing.
    -- Yidu Benda plant update: Yidu Benda completed its upgrade of the waste
       water system and passed the government's verification and testing of
       equipment in October 2007 and received "Environmental Influence
       Report" and "Safety Assessment Report" from the Yichang Environmental
       Protection Bureau and Yichang Safety Supervision Bureau in November and
       December of 2007, respectively. With this approval, Yidu Benda is
       allowed to perform
'/>"/>
SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Benda Pharmaceutical Files Amendment To Form S-1
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
7. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers
10. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
11. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... OAKS, Calif. , Feb. 26, 2015 ... achieved Gold Partner status in Oracle PartnerNetwork. In attaining ... for its commitment to establish Oracle-related knowledge in delivering ... the challenges of joint customers. Originally developed ... researchers to rapidly zoom in and out of massive ...
(Date:2/26/2015)... Feb. 26, 2015  Epic Sciences announced today that ... present at the 35th Annual Cowen and Company Health ... the MIT Room, 3rd Floor. The conference will be ... Mass. Epic is developing diagnostic tests of ... and proteomic changes that occur during the course of ...
(Date:2/26/2015)... -- Spark Therapeutics (NASDAQ: ONCE ) announced today ... the Cowen and Company Health Care Conference on Wednesday, ... Boston Marriott Copley Place. To access the ... Cowen conference, please visit the "Upcoming Events" section within ... website at www.sparktx.com .  A replay of the ...
(Date:2/26/2015)... York (PRWEB) February 26, 2015 On ... dedicated to building a nationwide Clostridium difficile (C. diff) ... C. diff burden study by the Centers for Disease ... diff caused almost half a million infections among Americans ... U.S. nursing homes. , The study also estimates ...
Breaking Biology Technology:Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... Monday, January 28, The Royal,Marsden Hospital (Sutton, ... Arc Therapy (VMAT)* treatment in the world ... treatment, the hospital,used its existing Elekta Synergy(R) ... system., (Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ), ...
... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) ... 2008 Small and Mid Cap Growth Conference in ... at 4:40 p.m. EST. Kevin,Hrusovsky, President and CEO ... the,company,s business. The live webcast can be accessed ...
... Germany and MINNEAPOLIS, Minnesota, February 11, Bayer HealthCare ... Minneapolis, MN, (Nasdaq: POSS ), announced today ... pursuant to which,MEDRAD will acquire Possis Medical in ... or a total equity value of approximately US-Dollar ...
Cached Biology Technology:Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ... period 2013 through 2020. Also, a seven-year historic analysis is provided ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
... old, have been ill, or suffered an injury, you,ve watched ... slight or gradualis about as common to the human condition ... little about what causes skeletal muscles to atrophy. They know ... and parsing the key actors from the poseurs is tricky. ...
... A broken chromosome is like an unmoored beansprout circling in ... with broken chromosomes, the cell will be killed and so ... Often, it finds a workable substitute: another nearby chromosome. When ... a similar process to exchange genetic material, you,ve got a ...
... found a way to replace up to 50 per cent ... Warwick chemists have taken out much of the cocoa butter ... with tiny droplets of juice measuring under 30 microns in ... dark and white chocolate using what is known as a ...
Cached Biology News:Researchers identify key culprit causing muscle atrophy 2Researchers identify key culprit causing muscle atrophy 3Chromosomal translocations point the way toward personalized cancer care 2Chromosomal translocations point the way toward personalized cancer care 3Fruity science halves fat in chocolate 2
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Request Info...
... Clone/PAD: 5B15-5B-11E. Immunogen: Synthetic peptide ... human MUC5B protein. Specificity: Specific ... protein. On Western blots it identifies the ... Human (positive controls: deglycosylated secreted media ...
Biology Products: